- Trials with a EudraCT protocol (297)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
297 result(s) found for: Relapsing-remitting.
Displaying page 4 of 15.
EudraCT Number: 2013-001422-25 | Sponsor Protocol Number: ITA-BGT-12-10389 | Start Date*: 2013-06-11 | |||||||||||
Sponsor Name:Biogen Idec Italia S.r.l. | |||||||||||||
Full Title: Single country study assessing cognition in Relapsing Remitting Multiple Sclerosis patients treated with BG00012 | |||||||||||||
Medical condition: Relapsing Remitting Multiple Sclerosis (RRMS) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-012716-40 | Sponsor Protocol Number: CO-200-201 | Start Date*: 2009-12-31 | |||||||||||
Sponsor Name:Peptimmune Inc. | |||||||||||||
Full Title: The Effect of the Dose of PI-2301 on Efficacy, Safety, and Tolerability, in Subjects with the Relapsing Remitting Form of Multiple Sclerosis: A Phase 2 Randomized, double-blind, four–arm, parallel,... | |||||||||||||
Medical condition: Relapsing-remitting multiple sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: EE (Prematurely Ended) CZ (Completed) DE (Completed) FR (Ongoing) PL (Prematurely Ended) SK (Completed) BG (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-003037-32 | Sponsor Protocol Number: 27178 | Start Date*: 2007-09-11 | |||||||||||
Sponsor Name:Merck Serono International SA | |||||||||||||
Full Title: A two-arm, randomized, double-blind, control group-compared, multicenter, phase IIIb study with monthly MRI and biomarker assessments to evaluate the efficacy, safety, and tolerability of Rebif® Ne... | |||||||||||||
Medical condition: Relapsing remitting Multiple Sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: LT (Completed) DE (Completed) EE (Completed) IT (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-002470-31 | Sponsor Protocol Number: MT-1303-E04 | Start Date*: 2012-10-29 | |||||||||||
Sponsor Name:Mitsubishi Tanabe Pharma Corporation (MTPC) | |||||||||||||
Full Title: A phase II, multicentre, randomised, double-blind, parallel group, placebo-controlled, dose-finding study to evaluate the safety and efficacy of three different oral doses of MT-1303 administered f... | |||||||||||||
Medical condition: Relapsing-Remitting Multiple Sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) LT (Completed) CZ (Completed) HU (Completed) FI (Completed) BE (Completed) IT (Completed) PL (Completed) BG (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-005450-23 | Sponsor Protocol Number: MS-LAQ-302 | Start Date*: 2008-03-17 | |||||||||||
Sponsor Name:Teva Pharmaceutical Industries Ltd | |||||||||||||
Full Title: Estudio multinacional, multicéntrico, randomizado, de grupos paralelos realizado en pacientes con Esclerosis Múltiple Remitente Recurrente (RRMS) para evaluar la eficacia, seguridad y tolerabilidad... | |||||||||||||
Medical condition: Esclerosis Múltiple Remitente Recurrente (RRMS) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) EE (Completed) CZ (Completed) IT (Completed) SK (Completed) LT (Completed) BG (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-003936-50 | Sponsor Protocol Number: 28063 | Start Date*: 2008-03-10 | |||||||||||
Sponsor Name:Merck Serono International S.A. | |||||||||||||
Full Title: Estudio en fase II, multicéntrico, aleatorizado, a doble ciego, con cuatro brazos y controlado frente a placebo, para evaluar, mediante RM frecuentes, la seguridad, tolerabilidad y eficacia de tres... | |||||||||||||
Medical condition: Esclerosis múltiple recidivante Relapsing multiple sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) FR (Completed) NL (Completed) BE (Completed) SE (Completed) AT (Prematurely Ended) CZ (Prematurely Ended) LT (Restarted) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-004334-41 | Sponsor Protocol Number: LAQ/5063OL | Start Date*: 2006-02-10 | |||||||||||
Sponsor Name:Teva Pharmaceutical Industries Ltd | |||||||||||||
Full Title: An active extension of LAQ/5062 study. A multinational, multicenter, randomized, double-blind, parallel-group study, to evaluate the safety, tolerability and efficacy of two doses (0.3 mg and 0.6 m... | |||||||||||||
Medical condition: Relapsing Remitting Multiple Sclerosis (RRMS) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) HU (Prematurely Ended) ES (Completed) DE (Completed) CZ (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-002283-25 | Sponsor Protocol Number: EMR200575-001 | Start Date*: 2013-12-18 | |||||||||||
Sponsor Name:Merck KGaA | |||||||||||||
Full Title: A Phase II, Randomized, Multi-center, Parallel-group, Rater-blinded Study To Evaluate the Efficacy, Safety and Tolerability of 0.5 mg, 3 mg, 10 mg and 20 mg Plovamer Acetate Doses Compared to Copax... | |||||||||||||
Medical condition: Relapsing Remitting Multiple Sclerosis (RRMS) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) HU (Completed) IT (Completed) GB (Completed) FI (Completed) GR (Completed) ES (Completed) BG (Completed) PL (Completed) HR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-004935-18 | Sponsor Protocol Number: GNC-004 | Start Date*: 2017-04-12 | |||||||||||
Sponsor Name:GeNeuro SA | |||||||||||||
Full Title: A Long-Term International, Extension of Study GNC-003, with GNbAC1 in Patients with Relapsing Remitting Multiple Sclerosis | |||||||||||||
Medical condition: Multiple Sclerosis (MS) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) DE (Prematurely Ended) CZ (Prematurely Ended) ES (Prematurely Ended) PL (Prematurely Ended) BG (Prematurely Ended) HR (Prematurely Ended) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-006465-16 | Sponsor Protocol Number: rhGH in MS | Start Date*: Information not available in EudraCT | ||||||||||||||||
Sponsor Name:University of Leipzig | ||||||||||||||||||
Full Title: Pilot trial of recombinant human growth hormone for remyelination in multiple sclerosis | ||||||||||||||||||
Medical condition: Multiple Sclerosis | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2010-024017-31 | Sponsor Protocol Number: CFTY720DIT02 | Start Date*: 2011-03-15 | |||||||||||
Sponsor Name:NOVARTIS FARMA | |||||||||||||
Full Title: A 6-month, Randomized, Active Comparator, Open-label, Multi-Center Study to Evaluate Patient OutComes, Safety and Tolerability of Fingolimod (FTY720) 0.5 mg/day in Patients with Relapsing Remitting... | |||||||||||||
Medical condition: Relapsing Remitting Multiple Sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-000674-31 | Sponsor Protocol Number: CFTY720DDE15TS | Start Date*: 2012-08-01 | |||||||||||
Sponsor Name:Novartis Pharma GmbH | |||||||||||||
Full Title: A 3-year, multi-center study to describe the long term changes of optical coherence tomography (OCT) parameters in patients under treatment with Gilenya® | |||||||||||||
Medical condition: RNFLT in Patients with relapsing remitting Multiple Sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-001055-12 | Sponsor Protocol Number: BIIT0212 | Start Date*: 2015-05-28 | |||||||||||
Sponsor Name:Biogen Idec Italia S.r.l. | |||||||||||||
Full Title: Flu-like syndrome Inhibition Giving anti-histaminic Therapy. Randomized cross-over, single-center, randomized, placebo-controlled, double-blind study to evaluate the efficacy of cetirizine on Flu-l... | |||||||||||||
Medical condition: Patients with relapsing remitting multiple sclerosis (RRMS) treated with interferoneβ, suffering from flu-like syndrome (FLS). | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-002201-11 | Sponsor Protocol Number: BIIT0215 | Start Date*: 2015-12-10 | |||||||||||
Sponsor Name:BIOGEN IDEC ITALIA S.R.L. | |||||||||||||
Full Title: Multicenter interventional Phase IV study for the assessment of the effects on patient’s satisfaction of Plegridy (pre-filled pen) in subjects with relapsing-remitting multiple sclerosis unsatisfie... | |||||||||||||
Medical condition: Subjects with relapsing-remitting multiple sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-008065-35 | Sponsor Protocol Number: TYNERGY | Start Date*: 2009-03-13 | ||||||||||||||||
Sponsor Name:BiogenIdec A/S | ||||||||||||||||||
Full Title: A multi-centre and prospective trial to evaluate the effects on mul-tiple sclerosis related fatigue during treatment with Tysabri® in patients with relapsing remitting multiple sclerosis over the c... | ||||||||||||||||||
Medical condition: Mutiple sclerosis related fatigue in subjects with relapsing remitting multiple sclerosis | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: SE (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2016-001515-20 | Sponsor Protocol Number: 12971/16 | Start Date*: 2016-10-20 | |||||||||||
Sponsor Name:UNIVERSITÀ CATTOLICA DEL SACRO CUORE- POLICLINICO A. GEMELLI | |||||||||||||
Full Title: EFFECT OF TERIFLUNOMIDE ON T CELL SUBPOPULATIONS IN PERIPHERAL BLOOD FROM RRMS PATIENTS | |||||||||||||
Medical condition: RELAPSING-REMITTING MULTIPLE SCLEROSIS | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-000365-19 | Sponsor Protocol Number: CFTY720D2301 | Start Date*: 2005-12-19 |
Sponsor Name:Novartis Pharma Services AG | ||
Full Title: A 24-month, double-blind, randomized, multicenter, placebo-controlled, parallel-group study comparing efficacy and safety of FTY720 1.25 mg and 0.5 mg administered orally once daily versus placebo ... | ||
Medical condition: Relapsing-remitting multiple sclerosis (RRMS) | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: SE (Completed) GB (Completed) CZ (Completed) DE (Completed) SK (Completed) FI (Completed) HU (Completed) GR (Completed) IE (Completed) EE (Completed) LT (Completed) | ||
Trial results: View results |
EudraCT Number: 2013-003884-71 | Sponsor Protocol Number: LPS13649 | Start Date*: 2015-02-05 | |||||||||||
Sponsor Name:Genzyme Corporation | |||||||||||||
Full Title: A long-term follow-up study for Multiple Sclerosis patients who have completed the alemtuzumab Extension Study (CAMMS03409) | |||||||||||||
Medical condition: Relapsing-remitting multiple sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) NL (Completed) CZ (Completed) ES (Completed) DE (Completed) IT (Completed) DK (Completed) HR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-002667-34 | Sponsor Protocol Number: WA39085 | Start Date*: 2020-03-06 | ||||||||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd | ||||||||||||||||||
Full Title: AN OPEN-LABEL, PARALLEL-GROUP STUDY TO EVALUATE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMIC EFFECTS OF OCRELIZUMAB IN CHILDREN AND ADOLESCENTS WITH RELAPSING-REMITTING MULTIPLE SCLE... | ||||||||||||||||||
Medical condition: Relapsing-remitting multiple sclerosis (MS) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||
Trial protocol: PL (Trial now transitioned) IT (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-005972-42 | Sponsor Protocol Number: 27571 | Start Date*: 2007-06-12 | |||||||||||
Sponsor Name:Merck Serono International SA | |||||||||||||
Full Title: A randomized, multicenter, two-arm, open-label, phase IIIb study to evaluate the satisfaction in relapsing Multiple Sclerosis subjects transitioning to Rebif® New Formulation (RNF) from Rebif® (Int... | |||||||||||||
Medical condition: Relapsing multiple sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
